PROGENICS PHARMACEUTICALS INC
SC 13G/A, 1999-02-16
PHARMACEUTICAL PREPARATIONS
Previous: PROGENICS PHARMACEUTICALS INC, SC 13G, 1999-02-16
Next: AMERICAN POWER CONVERSION CORPORATION, SC 13G/A, 1999-02-16



                              UNITED STATES
                    SECURITIES AND EXCHANGE COMMISSION
                          Washington, D.C. 20549


                              SCHEDULE 13G/A



                Under the Securities Exchange Act of 1934
                          (Amendment No.  1 )*

                     Progenics Pharmaceuticals, Inc.
                     -------------------------------
                             (Name of Issuer)

                 Common Stock, par value $.0013 per share
                 ----------------------------------------
                      (Title of Class of Securities)

                                743187106
                                ---------
                              (CUSIP Number)

                            December 31, 1998
                            -----------------
         (Date of Event which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:

    [ ] Rule 13d-1(b)

    [ ] Rule 13d-1(c)

    [x] Rule 13d-1(d)

*The remainder  of this  cover page  shall be  filled out  for a reporting
person's initial  filing on this form with respect to the subject class of
securities, and  for any subsequent amendment containing information which
would alter disclosures provided in a prior cover page.

The information  required in the remainder of this cover page shall not be
deemed to  be "filed"  for the  purpose of  Section 18  of the  Securities
Exchange Act  of 1934  ("Act") or  otherwise subject to the liabilities of
that section  of the  Act but  shall be subject to all other provisions of
the Act (however, see the Notes).
<PAGE>
                               SCHEDULE 13G/A

 CUSIP No.  743187106
- --------------------------------------------------------------------------

  1   NAMES OF REPORTING PERSONS
      S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

        Paul W. Maddon, M.D., Ph.D.

- --------------------------------------------------------------------------

  2   CHECK THE APPROPROPRIATE BOX IF A MEMBER OF A GROUP     (a)_____
                                                              (b)_____

- --------------------------------------------------------------------------

  3   SEC USE ONLY

- --------------------------------------------------------------------------

  4   CITIZENSHIP OR PLACE OF ORGANIZATION
        United States

- --------------------------------------------------------------------------

                 5   SOLE VOTING POWER
    NUMBER             792,010
      OF
    SHARES       6   SHARED VOTING POWER
 BENEFICIALLY          None
   OWNED BY
     EACH        7   SOLE DISPOSITIVE POWER
   REPORTING           792,010
    PERSON
     WITH        8   SHARED DISPOSITIVE POWER
                       None

- --------------------------------------------------------------------------

  9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
        1,191,784

- --------------------------------------------------------------------------

 10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
      SHARES (SEE INSTRUCTIONS)                                     __

- --------------------------------------------------------------------------

 11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
        12.6%

- --------------------------------------------------------------------------

 12   TYPE OF REPORTING PERSON
        IN

- --------------------------------------------------------------------------


                               -2-
<PAGE>
Item 1(a) Name of Issuer:

     Progenics Pharmaceuticals, Inc.


Item 1(a) Address of Issuer's Principal Executive Offices:

     777 Old Saw Mill River Road
     Tarrytown, New York  10591


Item 2(a) Name of Person Filing:

     Paul J. Maddon, M.D., Ph.D.


Item 2(b) Address of Principal Business Office or, if none,
          Residence:

     777 Old Saw Mill River Road
     Tarrytown, New York  10591


Item 2(c) Citizenship:

     United States of America


Item 2(d) Title of Class of Securities:

     Common Stock, par value $.0013 per share


Item 2(e) CUSIP Number:

     743187106


Item 3.   If this statement is filed pursuant to Rule 13d-1(b) or
          Rule 13d-2(b) or (c), check whether the person filing
          is a:

     Not applicable


Item 4.   Ownership

     Provide the following information regarding the aggregate
number and percentage of the class of securities of the issuer
identified in Item 1.

     (a)  Amount beneficially owned:  1,191,784 shares, including
          399,774 shares which the reporting person has the right
          to acquire within 60 days pursuant to the exercise of
          stock options granted by the issuer

     (b)  Percent of class:  12.6%


                               -3-
<PAGE>
     (c)  Number of shares as to which the person has:

          (i)   Sole power to vote or to direct the vote
                  792,010 shares

          (ii)  Shared power to vote or to direct the vote
                  none

          (iii) Sole power to dispose or to direct the
                disposition of
                  792,010 shares

          (iv)  Shared power to dispose or to direct the
                disposition of
                  none


Item 5.   Ownership of Five Percent or Less of a Class

     Not applicable


Item 6.   Ownership of More than Five Percent on Behalf of
          Another Person

     Not applicable


Item 7.   Identification and Classification of the Subsidiary
          Which Acquired the Security Being Reported on By the
          Parent Holding Company

     Not applicable


Item 8.   Identification and Classification of Members of the
          Group

     Not applicable


Item 9.   Notice of Dissolution of Group

     Not applicable


Item 10.  Certifications

     Not applicable


                                SIGNATURE

         After reasonable inquiry and to the best of my knowledge and
    belief, I certify that the information set forth in this
    statement is true, complete and correct.

                                          /s/ Paul J. Maddon    
                                       ---------------------------
    Dated:    February 10, 1999        Paul J. Maddon, M.D., Ph.D.


                                   -4-


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission